Drug Discovery Pipeline Overview 2011
|
|
- Prudence James
- 6 years ago
- Views:
Transcription
1 Guangzhou Institutes of Drug Discovery Pipeline Overview
2 Goal of the Pipeline Guangzhou Institutes of Mission: Capture the best ideas from the 3 scientific institutes at GIBH and translate the ideas into drug discovery projects. In the past there was no mechanism to transform a concept into a drug discovery project Lack of incentive, platform technologies, centralization and integration of disciplines GIBH Scientific Institute Stem Cell Biology & Regenerative Medicine (iscbrm) Chemical Biology (icb) Infection & Immunity (I3) Drug Discovery Pipeline (DDP) Drug Candidates & Clinical Trials DDP Goal: Provide the expertise, platform, key technologies, integrated project teams and funding to develop new drugs for the treatment of cancer, inflammation and infection. 2
3 Milestones for the Pipeline Guangzhou Institutes of 1. Create and centralize key technology groups to support projects 2. Form integrated teams to develop a sustainable pipeline of projects 3. Establish key international partnership to co-develop drugs 4. Create new companies in Guangzhou using IP matured in the Pipeline Drug Discovery Pipeline (DDP) 3
4 Milestone 1: Centralizing Key Technology Groups High Through-Put Screening (HTS) Capable of screening thousands of compounds per week in various enzyme and cell based assays at a low price Structural Biology & Crystallography Allows us to optimize lead compounds using computer aided design as well as virtual screening Pharmacokinetics/ADME Defines the PK and safety properties of our lead compounds Biomarkers Validates the efficacy and safety of our drugs in pre-clinical models Medicinal Chemistry Design, synthesis and formulation of new drugs with IP Bio-Therapeutics The use of proteins as active agents to treat diseases 4
5 Pipeline Organization in 2011 Guangzhou Institutes of Micky Tortorella (CTO) Administration: 3 FTE Chemistry (Ding Ke): Biology (Donghai Wu): 18 RA 11 RA Total Headcount is 53 full time employees Budget per year is > 23 M Targeted Headcount is 65 full time employees HTS (Zhengchao Tu): PK/ADME (Xiaorong Liu): Crystallography (J. Liu): 5 RA 9 RA 1 RA Biomarkers (S. Spillman): 2 RA Bio-Therapeutics (D. Yu): 2 RA 5
6 Impact of HTS (Milestone 1) Guangzhou Institutes of High Throughput Screening (HTS) group currently runs kinase, protease, and various cell-based assays to support several drug discovery projects at GIBH. Productivity Targets (Related diseases ) Hits identified Protein Kinases ABL (CML) and mutants 351 ALK (Cancer) 5 Kit (GIST) (Cancer) 231 EGFR (Breast and lung cancer) and mutants 347 Her2 (Breast cancer) 84 AKT1 (Cancer) 35 AKT2 (Cancer) 35 AKT3 (Cancer) 35 Proteases DPPIV (Diabetes) 50 DPP8 (Diabetes) 17 DPP9 (Diabetes) 38 Other molecular targets Neuraminidase S (Influenza) 32 Neuraminidase S (Influenza) 32 HDAC1(Cancer) 15 HDAC7 (Cancer) 15 Cell-based infectious diseases Influenza 62 Ev71(Enterovirus infection) 1 Team Members Cloning and expression >20 targets have been cloned and 7 of them have been transfected into insect cells and their purification are underway. 6
7 Impact of PK/ADME (Milestone 1) Pharmacokinetics (PK) group has been formed and centralized to support the drug discovery research at GIBH Guangzhou Institutes of The group is supporting several projects, including our lead oral kinase inhibitor project for the treatment of leukemia and an oral anti-inflammation compound program for the care of Alzheimer's disease Analysis Productivity Compounds Tested Pharmacokinetics 85 CNS penetration 7 Acute toxicity 10 Metabolic stability 35 Protein binding 28 Caco2 21 Drug drug interaction 81 Zebra Fish (Toxicity) 16 Rat air pouch 2 inflammation model Drug toxicity in rat 4 Human hepatocyte culture 2 Team Members 7
8 Guangzhou Institutes of Impact of Crystallography (Milestone 1) The Protein/Crystallography group is supporting projects in the DDP by (1) Expression of protein and crystallography, (2) Computer-aided drug design, (3) High-throughput virtual screening, and (4) Development of a super computer platform capable of virtually screening ~40M compounds Target ADAMTS4/5 Productivity Disease Arthritis Team Members p38 alpha, beta, delta, gamma ckit/akt1/egf R Plasmepsin II/IV/V G1B Cancer etc. Cancer etc. Malaria Diabetes etc. Examples of structural analysis enabling optimization of lead molecules for several projects 8
9 Guangzhou Institutes of Impact of Biomarkers (Milestone 1) Biomarker based chips for rapid detection of thousands of proteins in the blood are being developed. The chips will be used as diagnostics to determine the safety and efficacy of our lead drug candidates by monitoring the modulation of these biomarkers. Productivity Team Members 1. Developing micro-array chips Microarray Slides 2. Making Ab chips for rapid biomarker screening Oxidative modification 3. Validating Nucleic Acid Programmable Protein Arrays Cell free expression of target protein 9
10 Guangzhou Institutes of Impact of Medicinal Chemistry (Milestone1) Medicinal chemistry is designing and synthesizing novel drugs against multiple targets in several disease areas including cancer, arthritis, diabetes, CNS and infection. The new chemistries developed at GIBH enjoy strong intellectual property. Target Disease Productivity # of Compounds Team Members Cancer 300 Arthritis 100 Alzheimer s 200 Diabetes 100 Flu 120 Malaria 6 Pain 3 10
11 Guangzhou Institutes of Milestone 2: Formation of Project Teams Integration of medicinal chemistry and biology has been successful Project teams provide the critical mass and expertise needed to support and advance drugs in the pipeline Project Successful assimilation of several project teams: Biology Leader Team Members Protein Screening Enzymology Biomarker validation Animal models PK/ADME Safety Team Members Molecule design Synthesis Purity Crystallography Scale-up Formulations Chemistry Leader 1. Oral Kinase Inhibitor 2. Oral Anti-AD Compound 3. Anti-Inflammatory sirnas 4. Plasmepsin V Inhibitor 5. Chromene COX-2 Inhibitor Measurable impact! 11
12 Sustainable Pipeline of Projects (Milestone 2) Discovery Pre-Clinical Development Clinical Development Early Exploration ADAMTS-13 Cartilage Re-growth Hit Identification Lead Optimization Anti- ADAMTS Inhibitor Inflammatory sirnas 3 rd Gen. COX-2 Inhibitor Plasmepsin V Inhibitor Drug Candidate Selection 2 nd Gen. Kinase Inhibitor Oral Anti-AD drug Clinical Testing Current programs are developing drugs to treat Alzheimer's, leukemia, inflammation and infectious diseases 2 projects near Candidate Selection, 1 project at Lead Optimization, 3 projects at Hit Identification and several projects at Early Exploration 12
13 Advanced Projects (Milestone 2) Guangzhou Institutes of Disease: Leukemia (Ding Ke) 1 2 Alzheimer's (Wenhui Hu & Donghai Wu) Target: Kinases Neural Inflammation Drug: Oral small molecule Oral small molecule Mechanism of Action: Inhibition of several kinases linked to cancer metastasis Suppression of inflammation associated with amyloidal plaques Stage of Development: Candidate Selection Candidate Selection Time to IND filing: /2012 Pipeline will focus the majority of resources on these two projects in 2011 Resource to win! 13
14 3 rd Gen. Kinase Inhibitor for the treatment of Leukemia (Milestone 2) Guangzhou Institutes of Efficacy of D824 in a model of cancer Candidate compound D824 inhibits the resistant forms IC50 nm compd Bcr-Abl Bcr-Abl(T315I) K562 Ba/F3 (T315I) Imatinib 399 > Nilotinib 14 > Dasatinib 3.0 > D
15 Oral Anti-Alzheimer s Disease Drug (Milestone 2) Guangzhou Institutes of Candidate HWH-2-130: Biological profile of an oral anti-ad drug Compound 130 has excellent drug-like properties. The animal studies show that 130 blocks neuron-inflammation and is efficacious in models of Alzheimer s disease and stroke. Physical properties Rule of five No violations PD Activity in vitro 1.74nM, > Minozac 4000-fold PK Activity in vivo F%, T1/2 BBB penetration Metabolism 100 times more potent than Minozac 74.91%, 4.32 ± 2.62 h 3 times better than Minozac AUC(Brain/Plasma)=0.21 Stable in rat, human Safety Acute toxicity MTD > 2000mg/kg 60 % of Maximum Activity pM 0.1pM 100pM 10pM 1pM 100nM 10nM 1nM ZGF uM 10uM 1uM Treatment Concentration 1mM 游泳时间 (s) ## ** * * ### *** * *** 第一天第二天第三天第四天第五天 sham model 多奈哌齐 Minozac(2.5mg/kg) ZGF-2-130(0.25mg/kg) ZGF-2-130(0.025mg/kg) ZGF-2-130(0.0025mg/kg) *** In vitro activity In vivo activity Acute toxicity 15 ### ** ** **
16 Anti-Arthritis sirna Drugs for Local delivery into Joints (Milestone 2) (1) Slow Release sirna Drug Delivery System Biodegradable polymer (2) Intra-articular Strategy for Commercializing sirna in OA and RA nanoplexes sirna targeting inflammatory genes involved in OA and RA Drugs sirna-as001 Sustain Drug Release via specialized Delivery System Delivery Devices Positively charged nanoplexes Target Sites Chondrocytes Synoviocytes Bone cells Immune cells (RA) IC50~10pM Pre-filled syringes 16
17 Guangzhou Institutes of Milestone 3: International Partnerships Plasmepsin V Inhibitors for Malaria 3 rd Gen. COX-2 Inhibitors for Pain & Cancer The Center for World Health & Medicine, Saint Louis University Legacy Pfizer Scientists, Inventors of Celebrex GIBH GIBH Washington University 17
18 Milestone 4: Creating New Companies Guangzhou Institutes of Stem Cell Biology & Regenerative Medicine (iscbrm) Transfer of Intellectual Property 1 Chemical Biology (icb) Drug Discovery Pipeline (DDP) 2 Infection & Immunity (I3) Argo Biopharmaceuticals Ensures focused effort on the development of lead drugs into clinical trials Shares the burden of discovery across GIBH with the new companies Stimulates the local economy of Guangdong Province Stimulates both science and biotech in Southern China Measurable Impact: 2 companies created 18
19 Guangzhou Institutes of Mission of New Companies (Milestone 4) 1 2 Argo Biopharmaceuticals Product Line: 1. ipscs, derived from tissue of normal and diseased human specimens. 2. Protocols for directed differentiation of ipscs into different cell lineages. 3. human ipscs containing reporter genes Partner: Sigma, USA Operating Budget: 10 M/yr People: 10 full time employees Location: Guangzhou Product Line: 1. sirna based therapeutics. 2. Nano particle delivery systems. Partner: Venture Capital and Local Government Operating Budget: 6-7 M/yr People: 8 full time employees Location: Guangzhou 19
20 Introduction of Micky Tortorella Guangzhou Institutes of Experience in Drug Discovery 1. ( ): DuPont Chemical as a Research Scientist studying inflammatory diseases, matrix and proteinase biology. 2. ( ): Pharmacia as a Senior Principal Investigator and project leader in musculoskeletal diseases. 3. ( ): Pfizer as a Senior Principal Investigator and project leader in inflammatory diseases. 4. (2009-now): GIBH as Chief Technology Officer in drug discovery research Scientific Accomplishments Discoverer of Aggrecanase-1 and -2, enzymes responsible for the breakdown of cartilage in osteoarthritis, published in Science in1999. Co-inventor of novel and proprietary series of amino-2-indanol-based compounds as selective aggrecanase inhibitors published in JBC in Recipient of awards, including the PGRD Individual Achievement Award at Pfizer. Primary author on > 47 publications and inventor of 10 US patents. 20
leading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationThe Right Molecules. Designed. Delivered.
The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationFactor X. Factor IIa (thrombin)
Protease Inhibitors: Innovation Drives Drug Pipeline Figure 1.2. Schematic of the Coagulation Cascade Tissue damage or inflammation Initiation Factor VIIa / Tissue Factor (TF) Factor IX Factor X Factor
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationApplication of Deep Learning to Drug Discovery
Application of Deep Learning to Drug Discovery Hase T, Tsuji S, Shimokawa K, Tanaka H Tohoku Medical Megabank Organization, Tohoku University Current Situation of Drug Discovery Rapid increase of R&D expenditure
More informationNanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management
Nanotechnology: A Brief History and Its Convergence with Medicine Weston Daniel, PhD Director of Program Management Outline Introduction The Nanoscale Applications Realization of a Vision There s Plenty
More informationDiscovery and Development of Highly Selective and Orally Bioavailable Macrocyclic IDO-1 Inhibitors
Discovery and Development of Highly Selective and Orally Bioavailable Macrocyclic IDO-1 Inhibitors 1 Tim Briggs Senior Director, Medicinal Chemistry Ensemble Therapeutics Corp. Ensemble Therapeutics Corp.
More informationPharma Research Revolution in Drug Discovery
Pharma Research Revolution in Drug Discovery Wolfgang Hartwig Head of Research, Pharmaceuticals Business Group Life Science Revolution at the Turn of the Millennium 1992: Robotic screening 1999: New organs
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationThe Integrated Biomedical Sciences Graduate Program
The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to
More informationLecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry
Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Clinical proteomics is the application of proteomic approach to the field of medicine. Proteome of an organism changes
More informationValuing and Licensing Intellectual Property. Richard Williams
c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations
More informationPeptide libraries: applications, design options and considerations. Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST
Peptide libraries: applications, design options and considerations Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST Overview 1 2 3 4 5 Introduction Peptide library basics Peptide library design considerations
More informationApplication of Deep Learning to Drug Discovery
Application of Deep Learning to Drug Discovery Hiroshi Tanaka Tohoku Medical Megabank Orga nization, Tohoku University Current Situation of Drug Discovery Rapid increase of R&D expenditure More than 1B
More informationAdding value to Indigenous Knowledge through Scientific Innovation
THE WORLD BANK Adding value to Indigenous Knowledge through Scientific Innovation INTERNATIONAL WORKSHOP ON INDIGENOUS KNOWLEDGE Benoni, South Africa 9-11 February 2005 Marthinus Horak Programme CSIR Bio/Chemtek
More informationMRC Technology. A Life Science Specialist Technology Transfer Company. Skaggs School of Pharmacy and Pharmaceutical Sciences, December 2011
MRC Technology A Life Science Specialist Technology Transfer Company Skaggs School of Pharmacy and Pharmaceutical Sciences, December 2011 Dr John Kelly, Associate Director Business Development John.kelly@tech.mrc.ac.uk
More informationStem Cell Services. Driving Innovation for Stem Cell Researchers
Driving Innovation for Stem Cell Researchers Stem Cell Services Partner with us and have access to the most advanced and comprehensive stem cell services available today. 675 W. Kendall St. Cambridge,
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationDr Amy Prosser Careers in Research: Industry
www.rsb.org.uk Dr Amy Prosser Careers in Research: Industry @RoyalSocBio #BiologyWeek #RSBcareersDay Careers in Research: Working in the Pharma Industry Dr Amy Prosser My Career History 2011 Completed
More informationCOPYRIGHTED MATERIAL. IN THISchapter, we first give definitions of the assay and the bioassay. INTRODUCTION TO ASSAY DEVELOPMENT
CHAPTER1 INTRODUCTION TO ASSAY DEVELOPMENT IN THISchapter, we first give definitions of the assay and the bioassay. Drug discovery and development processes are then reviewed to show the role bioassay
More informationPCR Arrays. An Advanced Real-time PCR Technology to Empower Your Pathway Analysis
PCR Arrays An Advanced Real-time PCR Technology to Empower Your Pathway Analysis 1 Table of Contents 1. Introduction to the PCR Arrays 2. How PCR Arrays Work 3. Performance Data from PCR Arrays 4. Research
More informationHISTORY AND BACKGROUND
Integrated Technology Platform Protein Kinases for Drug Development in Oncology Christoph Sachsenmaier and Christoph Schäechtele ProQinase GmbH, Freiburg, Germany BioTechniques 33:S101-S106 (October 2002)
More informationOptimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationNovartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program
Novartis Business Services HR University Relations Clinical Sciences and Innovation Postgraduate Program 2 CLINICAL SCIENCES AND INNOVATION CLINICAL SCIENCES AND INNOVATION 3 The CS&I Postgraduate Program
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationSureSilencing sirna Array Technology Overview
SureSilencing sirna Array Technology Overview Pathway-Focused sirna-based RNA Interference Topics to be Covered Who is SuperArray? Brief Introduction to RNA Interference Challenges Facing RNA Interference
More informationDNA Microarray Technology
CHAPTER 1 DNA Microarray Technology All living organisms are composed of cells. As a functional unit, each cell can make copies of itself, and this process depends on a proper replication of the genetic
More informationThe research commercialisation office of the University of Oxford, previously called Isis Innovation, has been renamed Oxford University Innovation
The research commercialisation office of the University of Oxford, previously called Isis Innovation, has been renamed Oxford University Innovation All documents and other materials will be updated accordingly.
More informationPreclinical Drug Development
Preclinical Drug Development A guidance prepared by From a 2004 NIH Summit Workshop: A major reason for the tremendous cost of drug development is the high rate of drug candidate failure during clinical
More informationSYMBIOTIC HEALTH. Targeted GI Delivery of Orally Administered Cells and Proteins for Microbiome-Based Therapeutics
SYMBIOTIC HEALTH Targeted GI Delivery of Orally Administered Cells and Proteins for Microbiome-Based Therapeutics Contact: Gerard Honig PhD, Director ghonig@symbioticbio.com Overview Biotechnology startup
More informationTopical sirna for management of androgenic alopecia and oily skin Quark Pharmaceuticals, Inc.
Topical sirna for management of androgenic alopecia and oily skin 1 2017 Quark Pharmaceuticals, Inc. About Quark Founded in 1993; privately held Late stage pharmaceutical company with 2 Phase 3 programs,
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More informationThe Aptuit Center for Drug Discovery & Development Verona, Italy
The Aptuit Center for Drug Discovery & Development Verona, Italy 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable
More informationSingapore nanotechnology combats fatal brain infections
P ublic release date: 28-Jun-2009 Contact: Cathy Yarbrough sciencematter@yahoo.com 858-243-1814 Agency for Science, Technology and Research (A*STAR), Singapore Singapore nanotechnology combats fatal brain
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More informationApplied Protein Services
Applied Protein Services Applied Protein Services A Window into the Future Development risk and attrition rates remain two of the greatest challenges to a successful biopharmaceutical pipeline. To help
More informationManagement Discussion and Analysis for the Second quarter of FY
Management Discussion and Analysis for the Second quarter of FY 2016 17 Revenue Figures Consolidated (Rs. In Millions) Average conversion rate in Q2 FY 2016 17 considered is 66.85 /USD 1.00 Average conversion
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationHorizon 2020 funding opportunities for Regenerative Medicine ( ) Rudolf Fryček, PhD.
Horizon 2020 funding opportunities for Regenerative Medicine (2018-2020) Rudolf Fryček, PhD. Disclaimer: Any information mentioned is preliminary only, always consult the official documents. 1 Outline
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationDes cellules-souches dans le poumon : pourquoi faire?
Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland
More informationEvotec & Sanofi enter into exclusive negotiations for major multi-component strategic collaboration
Evotec & Sanofi enter into exclusive negotiations for major multi-component strategic collaboration Evotec AG, Investor and Analyst Call, 03 December 2014 Forward-looking statements Information set forth
More informationThe 3Rs: are Human Stem Cells and Organs on Chip alternatives?
The 3Rs: are Human Stem Cells and Organs on Chip alternatives? Towards precision medicine in future healthcare Christine Mummery Leiden University Medical Centre University Twente hdmt Three kinds of human
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationComparison of Commercial Transfection Reagents: Cell line optimized transfection kits for in vitro cancer research.
Comparison of Commercial Transfection Reagents: Cell line optimized transfection kits for in vitro cancer research. by Altogen Labs, 11200 Manchaca Road, Suite 203 Austin TX 78748 USA Tel. (512) 433-6177
More informationProgram overview. SciLifeLab - a short introduction. Advanced Light Microscopy. Affinity Proteomics. Bioinformatics.
Open House Program SciLifeLab Open House in Stockholm November 4, 2015 09:00-16:00 Contact: events@scilifelab.se Program overview 09:00-09:30-10:00-10:30-11:00-11:30-12:00-12:30-13:00-13:30-14:00-14:30-15:00-15:30-09:30
More informationThe science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy
More informationAffinity Reagents: The Landscape and Affimer Technology Competitive Advantages
Affinity Reagents: The Landscape and Affimer Technology Competitive Advantages Introduction It is well accepted that the limitations of antibodies present valuable commercial opportunities for alternative
More informationFlow CAST : Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3Kγ, BTK and SYK Activity
Flow CAST : Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3Kγ, BTK and SYK Activity Michele Romano, PhD Product Manager Flow CAST is for Research Use Only. Not for use in diagnostic procedures.
More informationGala s Gene Product Expression (GPEx ) Platform
Gala Biotech A Company with Gene Insertion and Manufacturing Technologies for the Next Generation of Gene Expression and Biologics Production Gala s Gene Product Expression (GPEx ) Platform Rapid creation
More informationWITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT
WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationBIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
More informationCM-352: a new, potent and safe molecule for the prevention and treatment of haemorrhage
XIV Encuentro de Cooperación Farma-Biotech CM-352: a new, potent and safe molecule for the prevention and treatment of haemorrhage Madrid, 17 de noviembre de 2015 Outline Institution: CIMA Project Partnering
More informationInnovating out of Crisis
Innovating out of Crisis Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation 1 st June, 2015 Business Fields of Fujifilm Group Digital Camera Photo book Optical devise FY2015/3 Digital minilab
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More informationThe Synthons Program Synergic collaboration between integrative biology and industrial biotech
The Synthons Program Synergic collaboration between integrative biology and industrial biotech Integrated research from feasibility study to industrial demonstration plant. Yvon Le Hénaff, General Manager,
More informationThe TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices
A leading Australian contract research organisation (CRO) providing integrated preclinical drug development services to the biotech and pharmaceutical industries The TetraQ Difference Located at The University
More informationOn Helix. 02 July Harren Jhoti President & CEO
On Helix 02 July 2014 Harren Jhoti President & CEO Astex Pharmaceuticals Global developer of small molecule drugs for unmet medical needs Expertise in oncology discovery & development World-class fragment-based
More informationDetermining the Predictive Validity of 3D Models & Achieving Standardization for Preclinical Efficacy Testing
Determining the Predictive Validity of 3D Models & Achieving Standardization for Preclinical Efficacy Testing August 28 2017 Jason Ekert, Head of Complex In Vitro Models Platform Technology and Sciences
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationQIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd
QIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd 1 Our current NGS & Bioinformatics Platform 2 Our NGS workflow and applications 3 QIAGEN s
More informationC o m p a n y R e p o r t
R C o m p a n y R e p o r t 2 0 0 6 G a l a p a g o s 2 0 0 6 S y n e r g y R Progressing a well-balanced therapeutic pipeline through innovative R&D in bone and joint diseases programs based on known
More informationTuberculosis Drug Accelerator
Tuberculosis Drug Accelerator Overview of Activities and Portfolio who, why, what, how, by when and where are we now Steve Berthel 1 What is the Tuberculosis Drug Accelerator? The A is a groundbreaking
More informationRapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products
RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August
More informationINTELLIGENT ANTIBODY DISCOVERY FROM HUMANS AND OTHER ANIMALS. Guy Cavet
INTELLIGENT ANTIBODY DISCOVERY FROM HUMANS AND OTHER ANIMALS Guy Cavet g.cavet@atreca.com PRECISION THERAPIES FROM THE ACTIVE IMMUNE RESPONSE Patient/Animal with Immune Response Immune Repertoire Capture
More informationCorporate Presentation. March 2018
Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationMarie Skłodowska-Curie European Fellowship
Marie Skłodowska-Curie European Fellowship Expression of Interest Application Form 2017 This form must be completed for Expressions of Interest (EoIs) to the Marie Skłodowska-Curie European Fellowship
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationUniversity of Pennsylvania Perelman School of Medicine High Throughput Screening Core
University of Pennsylvania Perelman School of Medicine High Throughput Screening Core Sara Cherry, Ph. D. David C. Schultz, Ph. D. dschultz@mail.med.upenn.edu (215) 573 9641 67 John Morgan Building Mission
More informationApplication of RNA Interference to Anti-Doping. Matthew Fedoruk, Ph.D. Gene & Cell Doping Symposium 2013, Beijing, China
Application of RNA Interference to Anti-Doping Matthew Fedoruk, Ph.D. Gene & Cell Doping Symposium 2013, Beijing, China From Plants to Worms to Humans: Discovery and Mechanism of RNAi Alnylam Pharmaceuticals
More informationPXBioVisioN. Protease Inhibition. Analysis of Peptides as Surrogates for Protease Activity to Monitor Protease Inhibition in-vivo
PXBioVisioN Protease Inhibition Analysis of Peptides as Surrogates for Protease Activity to Monitor Protease Inhibition in-vivo Peptides are Products of Protease Activity Peptidomics is defined as the
More informationChemical Peptide Synthesis in the Development of Protein Therapeutics
Chemical Peptide Synthesis in the Development of Protein Therapeutics Stephen Kent Abstract Effective automated SPPS is key to the synthesis of peptide building blocks for chemical protein synthesis, and
More informationAward Number: W81XWH TITLE: Direct inhibition of Skp2 for the Treatment of Advanced Prostate Cancer. PRINCIPAL INVESTIGATOR: Hyun-Suk Lim
AD Award Number: W81XWH-11-1-0286 TITLE: Direct inhibition of Skp2 for the Treatment of Advanced Prostate Cancer PRINCIPAL INVESTIGATOR: Hyun-Suk Lim CONTRACTING ORGANIZATION: Indiana University Indianapolis,
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationSPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
More informationThe Two-Hybrid System
Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine The Two-Hybrid System Carolina Vollert & Peter Uetz Institut für Genetik Forschungszentrum Karlsruhe PO Box 3640 D-76021 Karlsruhe
More informationLife Sciences Online Courses
Life Sciences Online Courses Table Of Contents Table of Contents How to Register 3 Learn Biotechnology Online 4 Learn MedDevice Online 5 Learn Molecular Diagnostics Online 6 Learn Biosafety & Biorisk Online
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationBL-7040: Oligonucleotide for Inflammatory Bowel Disease
BL-7040: Oligonucleotide for Inflammatory Bowel Disease December 2012 Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects,"
More informationBaek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationThe Yale Center for Molecular Discovery. A Core Research Facility at Yale s West Campus
The Yale Center for Molecular Discovery A Core Research Facility at Yale s West Campus This is one-stop shopping for scientists who are looking to take the next step in advancing their research. Scott
More informationJoint Technology Initiative: Innovative Medicine Initiative
Joint Technology Initiative: Innovative Medicine Initiative Dr John E Butler-Ransohoff Global External Innovation and Alliances Bayer HealthCare AG, Berlin/Wuppertal Bari, 30 April 2015 Largest Public
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationNucleic Acid Transfection. Genomics. TransIT Transfection Tools. Technical tip D.103
The nucleic acids delivery specialists design our transfection reagents. Our formulations provide superior transfection efficiency and cell viability. This complete range includes TransIT reagents, based
More informationPRIME-XV Cell Therapy Products by
PRIME-XV Cell Therapy Products by Product List 2017 TRINOVA BIOCHEM now distributes the PRIME-XV Cell Therapy line by Irvine Scientific in Germany, Austria and Switzerland. Irvine Scientific is a worldwide
More informationWhite Paper Authentic Recombinant Activin A and BMP- 4 Production Using HumanZyme s Proprietary Human Cell Line Expression Technology
White Paper Authentic Recombinant Activin A and BMP- 4 Production Using HumanZyme s Proprietary Human Cell Line Expression Technology Mark Azam, Ph.D. VP - R&D and Manufacturing Patricia Ahrweiler, Ph.D.
More informationOpportunities for industry/smes in EU-funded health research
Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005
More information